Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DIONISIO B YORRO

Allopathic & Osteopathic Physicians Emergency Medicine

NPI
1942245147
CMS profile
1295309
Location
GURNEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,436.84

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,436.84 68

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DIONISIO B YORRO

NPI 1942245147 · CMS profile ID 1295309

Allopathic & Osteopathic Physicians / Emergency Medicine

GURNEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DIONISIO B YORRO, NPI 1942245147, CMS profile ID 1295309. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DIONISIO B YORRO, NPI 1942245147, CMS profile ID 1295309. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DIONISIO B YORRO, NPI 1942245147, CMS profile ID 1295309, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $1,436.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $14.2404/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997092681 CMS
E.R. Squibb & Sons, L.L.C. $15.7104/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016397915 CMS
PFIZER INC. $18.9604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050391259 CMS
AstraZeneca Pharmaceuticals LP $22.4204/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015916097 CMS
Esperion Therapeutics, Inc. $19.4003/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050749461 CMS
Merck Sharp & Dohme LLC $19.9803/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048348149 CMS
Novo Nordisk Inc $15.8103/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000411087 CMS
Novartis Pharmaceuticals Corporation $16.3403/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993412587 CMS
Novo Nordisk Inc $6.7703/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000411041 CMS
Lilly USA, LLC $13.3603/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031460637 CMS
SANOFI-AVENTIS U.S. LLC $14.6403/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049628019 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.1402/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997149277 CMS
Merck Sharp & Dohme LLC $22.3602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048348117 CMS
Novo Nordisk Inc $4.9402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000411007 CMS
Novo Nordisk Inc $11.0102/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000411057 CMS
ABBVIE INC. $21.0601/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061399874 CMS
ABBVIE INC. $12.8501/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061399876 CMS
AstraZeneca Pharmaceuticals LP $60.9301/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015894083 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,558.08 117
PY2020 $1,862.11 99
PY2021 $2,220.68 123
PY2022 $1,767.67 92
PY2023 $1,436.84 68
PY2024 $1,651.45 78
PY2025 $982.69 44

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $75,470.00 86
PY2024 Recipient $50,126.00 35
PY2023 Recipient $30,526.00 35
PY2022 Recipient $74,554.00 88
PY2021 Recipient $44,830.00 79
PY2020 Recipient $30,828.00 53
PY2019 Recipient $10,249.00 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient ABBVIE INC. $3,260.00 12/05/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402872
Recipient ABBVIE INC. $620.00 12/05/2025 Covered Recipient Physician A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND IMMUNOGENICITY OF ABBV-277 IN HEALTHY ADULTS No dispute reported 06/30/2026 1202402877
Recipient ABBVIE INC. $860.00 12/05/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SC INJECTIONS AND IV INFUSTIONS OF ABBV-142 MOVE THROUGH THE BODY OF ADULT PARTICIPANTS No dispute reported 06/30/2026 1202402880
Recipient ABBVIE INC. $120.00 12/05/2025 Covered Recipient Physician A STUDY TO EVALUATE ADVERSE EVENTS HOW DRUG IS TOLERATED AND MOVES THROUGH THE BODY OF ABBV-8736 No dispute reported 06/30/2026 1202402884
Recipient ABBVIE INC. $270.00 12/05/2025 Covered Recipient Physician ARMOUR THYROID STUDY No dispute reported 06/30/2026 1202402888
Recipient ABBVIE INC. $1,690.00 12/05/2025 Covered Recipient Physician how the drug moves through the body and tolerability of orabl abbv-722capsules No dispute reported 06/30/2026 1202402892
Recipient ABBVIE INC. $30.00 12/05/2025 Covered Recipient Physician A STUDY TO ASSESS MULTIPLE ACCENDING DOSE, DRUG DRUG INTERACTION AND ASIAN PHARMACOKINETIC STUDY OF ABBV-1008 No dispute reported 06/30/2026 1202402896
Recipient ABBVIE INC. $1,350.00 12/05/2025 Covered Recipient Physician A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND IMMUNOGENICITY OF SINGLE ASCENDING SUBCUTANEOUS OR IV DOESES OF ABBV-701 No dispute reported 06/30/2026 1202402899
Recipient ABBVIE INC. $1,090.00 12/05/2025 Covered Recipient Physician A STUDY TO EVALUATE ADVERSE EVENTS HOW DRUG IS TOLERATED AND MOVES THROUGH THE BODY No dispute reported 06/30/2026 1202402903
Recipient ABBVIE INC. $6,560.00 11/13/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402833
Recipient ABBVIE INC. $150.00 11/13/2025 Covered Recipient Physician A STUDY TO ASSESS HOW THE DRUG MOVES THROUGH THE BODY ABBV-722 No dispute reported 06/30/2026 1202402838
Recipient ABBVIE INC. $1,220.00 11/13/2025 Covered Recipient Physician a study to evaluate the safety tolerability pharmacokinetics and immunogenicity of ABBV-701 No dispute reported 06/30/2026 1202402842
Recipient ABBVIE INC. $10.00 11/13/2025 Covered Recipient Physician ASESS HOW FOOD AFFECTS THE MOVEMENT OF ORAB ABBV-101 THROUGH THE BODY No dispute reported 06/30/2026 1202402846
Recipient ABBVIE INC. $290.00 11/13/2025 Covered Recipient Physician A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1202402849
Recipient ABBVIE INC. $1,540.00 11/13/2025 Covered Recipient Physician ASSESS THE ADVERSE EVENTS AND HOW SC AND IV OF ABBV-142 MOVE THROUGH THE BODY No dispute reported 06/30/2026 1202402853
Recipient ABBVIE INC. $210.00 11/13/2025 Covered Recipient Physician evaulate the bioavailabilty and food effects of oral venetoclax No dispute reported 06/30/2026 1202402857
Recipient ABBVIE INC. $330.00 11/13/2025 Covered Recipient Physician A study to assess the relative bioavailabilty of oral abbv-932 in healthy adults No dispute reported 06/30/2026 1202402861
Recipient ABBVIE INC. $140.00 11/13/2025 Covered Recipient Physician M25-966 Nimble Ph 1 TL1A UC DDI Study (n=16) No dispute reported 06/30/2026 1202402865
Recipient ABBVIE INC. $80.00 11/13/2025 Covered Recipient Physician a study to evaluate the safety tolerability pharmacokinetics and immunogenicity of abbv-277 No dispute reported 06/30/2026 1202402869
Recipient ABBVIE INC. $330.00 10/09/2025 Covered Recipient Physician A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS No dispute reported 06/30/2026 1202402788
Recipient ABBVIE INC. $1,740.00 10/09/2025 Covered Recipient Physician ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY No dispute reported 06/30/2026 1202402792
Recipient ABBVIE INC. $530.00 10/09/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402798
Recipient ABBVIE INC. $1,680.00 10/09/2025 Covered Recipient Physician EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES No dispute reported 06/30/2026 1202402802
Recipient ABBVIE INC. $50.00 10/09/2025 Covered Recipient Physician no details on this study are available No dispute reported 06/30/2026 1202402805
Recipient ABBVIE INC. $550.00 10/09/2025 Covered Recipient Physician A study to assess the relative bioavailability of risankizumab No dispute reported 06/30/2026 1202402809
Recipient ABBVIE INC. $1,140.00 10/09/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS No dispute reported 06/30/2026 1202402812
Recipient ABBVIE INC. $490.00 10/09/2025 Covered Recipient Physician A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants No dispute reported 06/30/2026 1202402815
Recipient ABBVIE INC. $310.00 10/09/2025 Covered Recipient Physician Nimble Phase1 TL1A UCDDI study No dispute reported 06/30/2026 1202402818
Recipient ABBVIE INC. $520.00 10/09/2025 Covered Recipient Physician A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1202402822
Recipient ABBVIE INC. $950.00 10/09/2025 Covered Recipient Physician PHASE 1 SAD MAD STUDY No dispute reported 06/30/2026 1202402826
Recipient ABBVIE INC. $1,140.00 10/09/2025 Covered Recipient Physician A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY No dispute reported 06/30/2026 1202402829
Recipient ABBVIE INC. $550.00 09/11/2025 Covered Recipient Physician A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1202402740
Recipient ABBVIE INC. $190.00 09/11/2025 Covered Recipient Physician A study to assess the relative bioavailability of risankizumab No dispute reported 06/30/2026 1202402744
Recipient ABBVIE INC. $790.00 09/11/2025 Covered Recipient Physician EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES No dispute reported 06/30/2026 1202402748
Recipient ABBVIE INC. $840.00 09/11/2025 Covered Recipient Physician A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants No dispute reported 06/30/2026 1202402752
Recipient ABBVIE INC. $270.00 09/11/2025 Covered Recipient Physician A study to assess the relative bioavailability of risankizumab No dispute reported 06/30/2026 1202402757
Recipient ABBVIE INC. $290.00 09/11/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS No dispute reported 06/30/2026 1202402761
Recipient ABBVIE INC. $3,010.00 09/11/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402765
Recipient ABBVIE INC. $120.00 09/11/2025 Covered Recipient Physician A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS No dispute reported 06/30/2026 1202402769
Recipient ABBVIE INC. $160.00 09/11/2025 Covered Recipient Physician A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY No dispute reported 06/30/2026 1202402772
Recipient ABBVIE INC. $700.00 09/11/2025 Covered Recipient Physician PHASE 1 SAD MAD STUDY No dispute reported 06/30/2026 1202402775
Recipient ABBVIE INC. $2,930.00 09/11/2025 Covered Recipient Physician A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants No dispute reported 06/30/2026 1202402780
Recipient ABBVIE INC. $1,490.00 09/11/2025 Covered Recipient Physician ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY No dispute reported 06/30/2026 1202402784
Recipient ABBVIE INC. $1,260.00 08/01/2025 Covered Recipient Physician PHASE 1 SAD MAD STUDY No dispute reported 06/30/2026 1202402668
Recipient ABBVIE INC. $2,490.00 08/01/2025 Covered Recipient Physician A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants No dispute reported 06/30/2026 1202402672
Recipient ABBVIE INC. $1,280.00 08/01/2025 Covered Recipient Physician A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY No dispute reported 06/30/2026 1202402675
Recipient ABBVIE INC. $1,000.00 08/01/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS No dispute reported 06/30/2026 1202402679
Recipient ABBVIE INC. $600.00 08/01/2025 Covered Recipient Physician EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES No dispute reported 06/30/2026 1202402685
Recipient ABBVIE INC. $120.00 08/01/2025 Covered Recipient Physician A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants No dispute reported 06/30/2026 1202402688
Recipient ABBVIE INC. $200.00 08/01/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS No dispute reported 06/30/2026 1202402692
Recipient ABBVIE INC. $1,050.00 08/01/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402695
Recipient ABBVIE INC. $190.00 08/01/2025 Covered Recipient Physician A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Ascending Oral Doses of ABBV-848 in Healthy Adult Subjects No dispute reported 06/30/2026 1202402699
Recipient ABBVIE INC. $1,400.00 08/01/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402702
Recipient ABBVIE INC. $980.00 08/01/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS No dispute reported 06/30/2026 1202402706
Recipient ABBVIE INC. $160.00 08/01/2025 Covered Recipient Physician A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants No dispute reported 06/30/2026 1202402709
Recipient ABBVIE INC. $1,110.00 08/01/2025 Covered Recipient Physician ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY No dispute reported 06/30/2026 1202402713
Recipient ABBVIE INC. $670.00 08/01/2025 Covered Recipient Physician EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES No dispute reported 06/30/2026 1202402717
Recipient ABBVIE INC. $930.00 08/01/2025 Covered Recipient Physician A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1202402721
Recipient ABBVIE INC. $1,780.00 08/01/2025 Covered Recipient Physician A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants No dispute reported 06/30/2026 1202402725
Recipient ABBVIE INC. $2,810.00 08/01/2025 Covered Recipient Physician ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY No dispute reported 06/30/2026 1202402728
Recipient ABBVIE INC. $1,160.00 08/01/2025 Covered Recipient Physician A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1202402732
Recipient ABBVIE INC. $930.00 08/01/2025 Covered Recipient Physician A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY No dispute reported 06/30/2026 1202402736
Recipient ABBVIE INC. $790.00 05/30/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS No dispute reported 06/30/2026 1202402637
Recipient ABBVIE INC. $1,670.00 05/30/2025 Covered Recipient Physician A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY No dispute reported 06/30/2026 1202402640
Recipient ABBVIE INC. $90.00 05/30/2025 Covered Recipient Physician A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS No dispute reported 06/30/2026 1202402645
Recipient ABBVIE INC. $140.00 05/30/2025 Covered Recipient Physician A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants No dispute reported 06/30/2026 1202402649
Recipient ABBVIE INC. $2,170.00 05/30/2025 Covered Recipient Physician Assess how the drug moves through the body, adverse events, and tolerability of ABBV-722 No dispute reported 06/30/2026 1202402653
Recipient ABBVIE INC. $1,270.00 05/30/2025 Covered Recipient Physician A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1202402656
Recipient ABBVIE INC. $1,150.00 05/30/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402659
Recipient ABBVIE INC. $80.00 05/30/2025 Covered Recipient Physician A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants No dispute reported 06/30/2026 1202402664
Recipient ABBVIE INC. $250.00 05/01/2025 Covered Recipient Physician A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants No dispute reported 06/30/2026 1202402615
Recipient ABBVIE INC. $100.00 05/01/2025 Covered Recipient Physician A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1202402618
Recipient ABBVIE INC. $880.00 05/01/2025 Covered Recipient Physician A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS No dispute reported 06/30/2026 1202402623
Recipient ABBVIE INC. $1,230.00 05/01/2025 Covered Recipient Physician A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY No dispute reported 06/30/2026 1202402626
Recipient ABBVIE INC. $410.00 05/01/2025 Covered Recipient Physician A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS No dispute reported 06/30/2026 1202402630
Recipient ABBVIE INC. $1,080.00 05/01/2025 Covered Recipient Physician Assess how the drug moves through the body, adverse events, and tolerability of ABBV-722 No dispute reported 06/30/2026 1202402633
Recipient ABBVIE INC. $170.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402577
Recipient ABBVIE INC. $90.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402580
Recipient ABBVIE INC. $50.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402584
Recipient ABBVIE INC. $750.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402586
Recipient ABBVIE INC. $420.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402591
Recipient ABBVIE INC. $240.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402595
Recipient ABBVIE INC. $980.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402599
Recipient ABBVIE INC. $90.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402603
Recipient ABBVIE INC. $160.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402607
Recipient ABBVIE INC. $500.00 02/27/2025 Covered Recipient Physician ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES No dispute reported 06/30/2026 1202402610